Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia

Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making

Luca Malcovati, Matteo Giovanni Della Porta, Cristiana Pascutto et al. · Journal of Clinical Oncology · 2005 · 860 citations · Full text

Medicine, Hematology, Clinical Epidemiology +15

Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major

Gary M. Brittenham, Patricia Griffith, Arthur W. Nienhuis et al. · New England Journal of Medicine · 1994 · 846 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

Maria Domenica Cappellini · Blood · 2005 · 719 citations · Full text

Medicine, Hematology, Pharmacology +13

Complications of β-thalassemia major in North America

Melody J. Cunningham, Eric A. Macklin, Ellis J. Neufeld et al. · Blood · 2004 · 450 citations

Medicine, Hematology, Internal Medicine +9

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

Mikkael A. Sekeres, Richard M. Stone, David Zahrieh et al. · Leukemia · 2004 · 205 citations

Medicine, Geriatric Medicine, Internal Medicine +16